{"component": "clause", "props": {"groups": [{"snippet_links": [{"key": "no-party", "type": "clause", "offset": [0, 8]}, {"key": "related-to", "type": "clause", "offset": [36, 46]}, {"key": "mutual-termination", "type": "clause", "offset": [66, 84]}, {"key": "notice-of-a", "type": "clause", "offset": [88, 99]}, {"key": "unilateral-termination", "type": "clause", "offset": [100, 122]}, {"key": "to-the-extent", "type": "clause", "offset": [134, 147]}, {"key": "commitments-and-contracts", "type": "clause", "offset": [181, 206]}, {"key": "termination-date", "type": "definition", "offset": [214, 230]}], "samples": [{"hash": "gx6HR9KPmAk", "uri": "/contracts/gx6HR9KPmAk#new-commitments", "label": "Cooperative Research and Development Agreement", "score": 31.3408622742, "published": true}, {"hash": "hx8mTNUodyB", "uri": "/contracts/hx8mTNUodyB#new-commitments", "label": "Cooperative Research and Development Agreement", "score": 26.1704311371, "published": true}, {"hash": "fb4n8NOe2rD", "uri": "/contracts/fb4n8NOe2rD#new-commitments", "label": "Cooperative Research and Development Agreement (Newlink Genetics Corp)", "score": 21.9691982269, "published": true}], "size": 31, "snippet": "No Party shall make new commitments related to this CRADA after a mutual termination or notice of a unilateral termination and shall, to the extent feasible, cancel all outstanding commitments and contracts by the termination date.", "hash": "f54e455e0251a80c6ed47d2464522000", "id": 2}, {"snippet_links": [{"key": "neither-party", "type": "definition", "offset": [0, 13]}, {"key": "related-to", "type": "clause", "offset": [38, 48]}, {"key": "after-expiration", "type": "clause", "offset": [60, 76]}, {"key": "mutual-termination", "type": "clause", "offset": [78, 96]}, {"key": "notice-of-a", "type": "clause", "offset": [103, 114]}, {"key": "unilateral-termination", "type": "clause", "offset": [115, 137]}, {"key": "to-the-extent", "type": "clause", "offset": [148, 161]}, {"key": "commitments-and-contracts", "type": "clause", "offset": [195, 220]}, {"key": "termination-date", "type": "definition", "offset": [228, 244]}, {"key": "authority-to", "type": "definition", "offset": [295, 307]}, {"key": "subsequent-to-the", "type": "clause", "offset": [359, 376]}, {"key": "expiration-or-termination", "type": "clause", "offset": [377, 402]}, {"key": "term-of-the", "type": "clause", "offset": [455, 466]}, {"key": "research-and-development-activities", "type": "clause", "offset": [492, 527]}, {"key": "research-plan", "type": "definition", "offset": [545, 558]}], "samples": [{"hash": "kdfUt8L3aWT", "uri": "/contracts/kdfUt8L3aWT#new-commitments", "label": "Cooperative Research and Development Agreement", "score": 31.6812076569, "published": true}, {"hash": "aslzHuR9mSZ", "uri": "/contracts/aslzHuR9mSZ#new-commitments", "label": "Cooperative Research and Development Agreement", "score": 31.3408622742, "published": true}, {"hash": "8YP4jSO9hYH", "uri": "/contracts/8YP4jSO9hYH#new-commitments", "label": "Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)", "score": 27.0068454742, "published": true}], "size": 60, "snippet": "Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD will have the authority to retain and expend any funds for up to one (1) year subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan.", "hash": "240ce565b9e07fc10ead8f9229db7879", "id": 1}, {"snippet_links": [{"key": "at-any-time", "type": "clause", "offset": [0, 11]}, {"key": "primary-syndication", "type": "definition", "offset": [36, 55]}, {"key": "the-lead-arrangers", "type": "clause", "offset": [74, 92]}, {"key": "prior-to-the", "type": "clause", "offset": [98, 110]}, {"key": "in-the-case", "type": "clause", "offset": [148, 159]}, {"key": "revolving-facility-loans", "type": "clause", "offset": [163, 187]}, {"key": "revolving-facility-maturity-date", "type": "definition", "offset": [193, 225]}, {"key": "term-loan-maturity-date", "type": "definition", "offset": [266, 289]}, {"key": "notice-to-the-administrative-agent", "type": "clause", "offset": [318, 352]}, {"key": "to-request", "type": "clause", "offset": [359, 369]}, {"key": "new-revolving-lenders", "type": "clause", "offset": [370, 391]}, {"key": "to-provide", "type": "clause", "offset": [392, 402]}, {"key": "new-revolving-facility-commitments", "type": "definition", "offset": [403, 437]}, {"key": "new-term-lenders", "type": "definition", "offset": [485, 501]}, {"key": "loans-hereunder", "type": "clause", "offset": [550, 565]}, {"key": "aggregate-principal-amount", "type": "definition", "offset": [672, 698]}, {"key": "not-to-exceed", "type": "definition", "offset": [728, 741]}, {"key": "dollar-equivalent", "type": "definition", "offset": [746, 763]}, {"key": "general-corporate-purposes", "type": "clause", "offset": [825, 851]}, {"key": "capital-expenditure", "type": "definition", "offset": [879, 898]}, {"key": "restricted-payment", "type": "definition", "offset": [900, 918]}, {"key": "repayment-of-other-indebtedness", "type": "clause", "offset": [922, 953]}, {"key": "each-case", "type": "definition", "offset": [958, 967]}, {"key": "this-agreement", "type": "clause", "offset": [997, 1011]}, {"key": "increased-amount-date", "type": "definition", "offset": [1055, 1076]}, {"key": "new-term-commitments", "type": "definition", "offset": [1123, 1143]}, {"key": "days-after", "type": "definition", "offset": [1205, 1215]}, {"key": "the-company-shall", "type": "clause", "offset": [1491, 1508]}, {"key": "notify-the-administrative-agent", "type": "clause", "offset": [1509, 1540]}, {"key": "in-writing", "type": "clause", "offset": [1541, 1551]}, {"key": "each-lender", "type": "clause", "offset": [1571, 1582]}, {"key": "other-financial-institution", "type": "clause", "offset": [1586, 1613]}, {"key": "new-revolving-facility-lender", "type": "definition", "offset": [1722, 1751]}, {"key": "revolving-facility-lenders", "type": "definition", "offset": [1846, 1872]}, {"key": "new-lenders", "type": "clause", "offset": [1879, 1890]}, {"key": "in-accordance-with", "type": "definition", "offset": [1904, 1922]}, {"key": "prior-sentence", "type": "definition", "offset": [1927, 1941]}, {"key": "provided-that", "type": "clause", "offset": [1990, 2003]}, {"key": "a-portion", "type": "definition", "offset": [2043, 2052]}, {"key": "sole-discretion", "type": "clause", "offset": [2106, 2121]}, {"key": "provide-a", "type": "definition", "offset": [2126, 2135]}, {"key": "loans-shall", "type": "definition", "offset": [2218, 2229]}, {"key": "original-dollar-term-loans", "type": "definition", "offset": [2444, 2470]}, {"key": "all-purposes", "type": "clause", "offset": [2524, 2536]}, {"key": "additional-dollar-term-loans", "type": "definition", "offset": [2610, 2638]}, {"key": "additional-euro-term-loans", "type": "definition", "offset": [2642, 2668]}, {"key": "to-the-extent", "type": "clause", "offset": [2746, 2759]}, {"key": "applicable-margin", "type": "definition", "offset": [2769, 2786]}, {"key": "repayment-schedule", "type": "definition", "offset": [2790, 2808]}, {"key": "applicable-to", "type": "definition", "offset": [2861, 2874]}, {"key": "the-original", "type": "clause", "offset": [2875, 2887]}, {"key": "default-shall", "type": "definition", "offset": [3112, 3125]}, {"key": "after-giving", "type": "clause", "offset": [3171, 3183]}, {"key": "joinder-agreements", "type": "definition", "offset": [3275, 3293]}, {"key": "new-commitment-joinder-agreement", "type": "definition", "offset": [3304, 3336]}, {"key": "executed-and-delivered", "type": "clause", "offset": [3339, 3361]}, {"key": "administrative-agent-by", "type": "definition", "offset": [3369, 3392]}, {"key": "and-documentation", "type": "clause", "offset": [3455, 3472]}, {"key": "designated-maturity", "type": "definition", "offset": [3540, 3559]}, {"key": "if-applicable", "type": "definition", "offset": [3571, 3584]}, {"key": "amortization-schedule", "type": "definition", "offset": [3586, 3607]}, {"key": "the-new-term-loans", "type": "clause", "offset": [3613, 3631]}, {"key": "the-register", "type": "clause", "offset": [3663, 3675]}, {"key": "the-requirements", "type": "clause", "offset": [3711, 3727]}, {"key": "fees-and-expenses", "type": "definition", "offset": [3927, 3944]}, {"key": "in-respect-of", "type": "clause", "offset": [3999, 4012]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [4198, 4217]}, {"key": "this-clause", "type": "clause", "offset": [4218, 4229]}, {"key": "compliance-with-the", "type": "clause", "offset": [4261, 4280]}, {"key": "incurrence-ratios", "type": "definition", "offset": [4281, 4298]}, {"key": "pro-forma-basis", "type": "clause", "offset": [4304, 4319]}, {"key": "assets-to-be", "type": "clause", "offset": [4469, 4481]}, {"key": "business-of-holdings-and-its-subsidiaries", "type": "clause", "offset": [4494, 4535]}], "samples": [{"hash": "84B3YSI25KY", "uri": "/contracts/84B3YSI25KY#new-commitments", "label": "Credit Agreement (Celanese CORP)", "score": 21.402463913, "published": true}, {"hash": "7zNfpzCmnqe", "uri": "/contracts/7zNfpzCmnqe#new-commitments", "label": "Credit Agreement (Celanese CORP)", "score": 21.0, "published": true}], "size": 13, "snippet": "At any time after completion of the primary syndication (as determined by the Lead Arrangers) and prior to the date which is 12 months prior to (i) in the case of Revolving Facility Loans, the Revolving Facility Maturity Date and (ii) in the case of Term Loans, the Term Loan Maturity Date, the Company may by written notice to the Administrative Agent elect to request New Revolving Lenders to provide new Revolving Facility Commitments (the \u201cNew Revolving Facility Commitments\u201d) and New Term Lenders to provide Commitments to make incremental Term Loans hereunder (\u201cNew Term Loans\u201d and, together with the New Revolving Facility Commitments, the \u201cNew Commitments\u201d) in an aggregate principal amount for all such New Commitments not to exceed the Dollar Equivalent of $500.0 million, the proceeds of which may be used for any general corporate purposes (including any Investment, Capital Expenditure, Restricted Payment or repayment of other Indebtedness, in each case as otherwise permitted under this Agreement). Such notice shall specify the date (the \u201cIncreased Amount Date\u201d) on which the Company proposes that the such New Term Commitments take effect, which shall be a date not less than 10 Business Days after the date on which such notice is delivered to the Administrative Agent and prior to the date which is 12 months prior to, in the case of New Revolving Facility Commitments, the Revolving Facility Maturity Date and, in the case of New Term Loans, the Term Loan Maturity Date. The Company shall notify the Administrative Agent in writing of the identity of each Lender or other financial institution reasonably acceptable to the Administrative Agent to whom such new Revolving Facility Commitments (each, a \u201cNew Revolving Facility Lender\u201d) and/or Commitments for New Term Loans (each, a \u201cNew Term Lender\u201d and, together with the New Revolving Facility Lenders, the \u201cNew Lenders\u201d) have been (in accordance with the prior sentence) allocated and the amounts of such allocations; provided that any Lender requested to provide all or a portion of such New Commitments may elect or decline, in its sole discretion, to provide a New Commitment. New Revolving Facility Commitments shall take effect and New Term Loans shall be made on the Increased Amount Date; provided that (1) all such New Commitments may be made in Dollars or Euros only, (2) all such New Term Loans shall be added to, and thereafter constitute, the then outstanding Original Dollar Term Loans or Original Euro Term Loans, as the case may be, for all purposes hereunder, although the Company may elect to designate New Term Loans as Additional Dollar Term Loans or Additional Euro Term Loans, as the case may be, hereunder by written notice to the Administrative Agent to the extent that the Applicable Margin or repayment schedule for such New Term Loans will be different than that applicable to the Original Dollar Term Loans or Original Euro Term Loans, as the case may be, or any Additional Dollar Term Loans or Additional Euro Term Loans, as the case may be, theretofore incurred and then outstanding, (3) no Default or Event of Default shall exist on the Increased Amount Date before or after giving effect to such New Commitments, (4) such New Commitments shall be evidenced by one or more joinder agreements (each, a \u201cNew Commitment Joinder Agreement\u201d) executed and delivered to the Administrative Agent by each New Lender, as applicable, on terms (other than pricing) and documentation reasonably satisfactory to the Administrative Agent, including the designated maturity date (and, if applicable, amortization schedule) for the New Term Loans, and each shall be recorded in the Register, each of which shall be subject to the requirements set forth in Section 2.17(e), (5) the aggregate principal amount of all New Revolving Facility Commitments shall not exceed the Dollar Equivalent of $250.0 million, (6) all reasonable and documented fees and expenses owing to the Administrative Agent and the New Lenders in respect of the New Commitments shall be paid on the Increased Amount Date and (7) immediately after giving effect to the incurrence of the New Commitments (which shall be deemed to be outstanding for the purposes of this clause (7)), Holdings shall (x) be in compliance with the Incurrence Ratios on a Pro Forma Basis or (y) the proceeds of such New Term Loans or loans under New Revolving Facility Commitments shall be used to purchase, construct or improve capital assets to be used in the business of Holdings and its Subsidiaries or to finance acquisitions permitted under this Agreement.", "hash": "f1b4d17546b14771842edbaf63874eac", "id": 3}, {"snippet_links": [{"key": "at-any-time", "type": "clause", "offset": [0, 11]}, {"key": "notice-to-the-administrative-agent", "type": "clause", "offset": [40, 74]}, {"key": "to-request", "type": "clause", "offset": [81, 91]}, {"key": "existing-revolving-facility-commitments", "type": "definition", "offset": [111, 150]}, {"key": "new-revolving-facility-commitments", "type": "definition", "offset": [176, 210]}, {"key": "in-the-aggregate", "type": "definition", "offset": [453, 469]}, {"key": "lesser-amount", "type": "clause", "offset": [475, 488]}, {"key": "integral-multiples", "type": "definition", "offset": [492, 510]}, {"key": "increased-amount-date", "type": "definition", "offset": [573, 594]}, {"key": "in-the-case", "type": "clause", "offset": [657, 668]}, {"key": "made-available", "type": "clause", "offset": [738, 752]}, {"key": "the-company-shall", "type": "clause", "offset": [754, 771]}, {"key": "notify-the-administrative-agent", "type": "clause", "offset": [772, 803]}, {"key": "in-writing", "type": "clause", "offset": [804, 814]}, {"key": "each-lender", "type": "clause", "offset": [834, 845]}, {"key": "other-financial-institution", "type": "clause", "offset": [849, 876]}, {"key": "new-revolving-facility-lender", "type": "definition", "offset": [937, 966]}, {"key": "incremental-term-lender", "type": "clause", "offset": [973, 996]}, {"key": "new-lender", "type": "definition", "offset": [1015, 1025]}, {"key": "provided-that", "type": "clause", "offset": [1028, 1041]}, {"key": "ineligible-institution", "type": "definition", "offset": [1045, 1067]}, {"key": "in-accordance-with", "type": "definition", "offset": [1128, 1146]}, {"key": "prior-sentence", "type": "definition", "offset": [1151, 1165]}, {"key": "to-provide", "type": "clause", "offset": [1250, 1260]}, {"key": "a-portion", "type": "definition", "offset": [1268, 1277]}, {"key": "sole-discretion", "type": "clause", "offset": [1330, 1345]}, {"key": "provide-a", "type": "definition", "offset": [1350, 1359]}, {"key": "become-effective", "type": "clause", "offset": [1403, 1419]}, {"key": "the-conditions", "type": "clause", "offset": [1560, 1574]}, {"key": "the-required-lenders", "type": "clause", "offset": [1662, 1682]}, {"key": "after-giving", "type": "clause", "offset": [1723, 1735]}, {"key": "commitments-and-loans", "type": "clause", "offset": [1755, 1776]}, {"key": "the-revolving-facility", "type": "clause", "offset": [1799, 1821]}, {"key": "loans-shall", "type": "definition", "offset": [1862, 1873]}, {"key": "joinder-agreements", "type": "definition", "offset": [1902, 1920]}, {"key": "executed-and-delivered", "type": "clause", "offset": [1921, 1943]}, {"key": "administrative-agent-by", "type": "definition", "offset": [1947, 1970]}, {"key": "the-register", "type": "clause", "offset": [2033, 2045]}, {"key": "the-requirements", "type": "clause", "offset": [2137, 2153]}, {"key": "the-borrowers", "type": "clause", "offset": [2192, 2205]}, {"key": "payments-required", "type": "definition", "offset": [2221, 2238]}, {"key": "pursuant-to-section", "type": "definition", "offset": [2239, 2258]}, {"key": "in-connection-with", "type": "clause", "offset": [2264, 2282]}, {"key": "the-provisions-of-the", "type": "clause", "offset": [2283, 2304]}, {"key": "with-respect-to", "type": "clause", "offset": [2337, 2352]}, {"key": "incremental-term-loans-incurred", "type": "clause", "offset": [2357, 2388]}, {"key": "purpose-of-financing", "type": "clause", "offset": [2405, 2425]}, {"key": "a-limited", "type": "clause", "offset": [2426, 2435]}, {"key": "date-of-execution", "type": "definition", "offset": [2603, 2620]}, {"key": "agreement-by-the-parties", "type": "clause", "offset": [2671, 2695]}, {"key": "default-shall", "type": "definition", "offset": [2708, 2721]}, {"key": "the-borrowing", "type": "clause", "offset": [2859, 2872]}, {"key": "event-of-default-under", "type": "definition", "offset": [2928, 2950]}, {"key": "in-existence", "type": "definition", "offset": [2987, 2999]}, {"key": "pro-forma-basis", "type": "clause", "offset": [3058, 3073]}, {"key": "concurrent-transactions", "type": "definition", "offset": [3104, 3127]}, {"key": "use-of-proceeds", "type": "definition", "offset": [3161, 3176]}, {"key": "the-representations-and-warranties", "type": "clause", "offset": [3190, 3224]}, {"key": "article-iii", "type": "clause", "offset": [3238, 3249]}, {"key": "true-and-correct", "type": "clause", "offset": [3259, 3275]}, {"key": "in-all-material-respects", "type": "definition", "offset": [3276, 3300]}, {"key": "the-applicable", "type": "clause", "offset": [3332, 3346]}, {"key": "except-to-the-extent", "type": "clause", "offset": [3416, 3436]}, {"key": "representations-or-warranties", "type": "clause", "offset": [3446, 3475]}, {"key": "materiality-qualifier", "type": "definition", "offset": [3671, 3692]}, {"key": "applicable-to", "type": "definition", "offset": [3734, 3747]}, {"key": "representations-and-warranties-to", "type": "clause", "offset": [4012, 4045]}, {"key": "by-the-lenders", "type": "clause", "offset": [4071, 4085]}], "samples": [{"hash": "cSSC1mhNswd", "uri": "/contracts/cSSC1mhNswd#new-commitments", "label": "Credit Agreement (Chart Industries Inc)", "score": 28.8466796875, "published": true}], "size": 11, "snippet": "At any time, the Company may by written notice to the Administrative Agent elect to request an increase to the existing Revolving Facility Commitments (any such increase, the \u201cNew Revolving Facility Commitments\u201d) and/or enter into one or more tranches of term loans (any such tranche, the \u201cIncremental Term Loans\u201d and together with the New Revolving Facility Commitments, if any, the \u201cNew Commitments\u201d), by an amount not in excess of U.S.$225.0 million in the aggregate or a lesser amount in integral multiples of U.S.$25.0 million. Such notice shall specify the date (an \u201cIncreased Amount Date\u201d) on which the Company proposes that the New Commitments and, in the case of Incremental Term Loans, the date for borrowing, as applicable, be made available. The Company shall notify the Administrative Agent in writing of the identity of each Lender or other financial institution reasonably acceptable to the Administrative Agent (each, a \u201cNew Revolving Facility Lender,\u201d an \u201cIncremental Term Lender\u201d or generally, a \u201cNew Lender\u201d; provided that no Ineligible Institution may be a New Lender) to whom the New Commitments have been (in accordance with the prior sentence) allocated and the amounts of such allocations; provided that any Lender approached to provide all or a portion of the New Commitments may elect or decline, in its sole discretion, to provide a New Commitment. Such New Commitments shall become effective as of such Increased Amount Date, and in the case of Incremental Term Loans, shall be made on such Increased Amount Date; provided that (1) the conditions set forth in paragraphs of (b) and (c) of Section 4.02 shall be satisfied or waived by the Required Lenders on such Increased Amount Date before or after giving effect to such New Commitments and Loans; (2) such increase in the Revolving Facility Commitments and/or the Incremental Term Loans shall be evidenced by one or more joinder agreements executed and delivered to Administrative Agent by each New Lender, as applicable, and each shall be recorded in the register, each of which shall be reasonably satisfactory to the Administrative Agent and subject to the requirements set forth in Section 2.17(e); and (3) the Borrowers shall make any payments required pursuant to Section 2.16 in connection with the provisions of the New Commitments; provided that, with respect to any Incremental Term Loans incurred for the primary purpose of financing a Limited Conditionality Acquisition (\u201cAcquisition-Related Incremental Term Loans\u201d), clause (1) of this sentence shall be deemed to have been satisfied so long as (A) as of the date of execution of the related Limited Conditionality Acquisition Agreement by the parties thereto, no Default shall have occurred and be continuing or would result from entry into such Limited Conditionality Acquisition Agreement, (B) as of the date of the borrowing of such Acquisition-Related Incremental Term Loans, no Event of Default under Section 7.01(a), (b), (h) or (i) is in existence immediately before or after giving effect (including on a Pro Forma Basis) to such borrowing and to any concurrent transactions and any substantially concurrent use of proceeds thereof, (C) the representations and warranties set forth in Article III shall be true and correct in all material respects as of the date of execution of the applicable Limited Conditionality Acquisition Agreement by the parties thereto, except to the extent any such representations or warranties are expressly limited to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such specified earlier date (provided that no materiality qualifier set forth in this subclause (C) shall be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) and (D) as of the date of the borrowing of such Acquisition-Related Incremental Term Loans, customary \u201cSungard\u201d representations and warranties (with such representations and warranties to be reasonably determined by the Lenders providing such Acquisition-Related Incremental Term Loans) shall be true and correct in all material respects immediately before and after giving effect to the incurrence of such Acquisition-Related Incremental Term Loans, except to the extent any such representations or warranties are expressly limited to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such specified earlier date (provided that no materiality qualifier set forth in this subclause (D) shall be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof).", "hash": "09132174499849b17703c4a3cb916387", "id": 4}, {"snippet_links": [{"key": "research-organization", "type": "definition", "offset": [4, 25]}, {"key": "this-agreement", "type": "clause", "offset": [69, 83]}, {"key": "receipt-of-a", "type": "clause", "offset": [91, 103]}, {"key": "termination-notice", "type": "definition", "offset": [112, 130]}, {"key": "to-the-extent", "type": "clause", "offset": [152, 165]}, {"key": "commitments-and-contracts", "type": "clause", "offset": [199, 224]}, {"key": "termination-date", "type": "definition", "offset": [232, 248]}], "samples": [{"hash": "9AcRLWgP2qC", "uri": "/contracts/9AcRLWgP2qC#new-commitments", "label": "Research Agreement", "score": 30.3145561218, "published": true}, {"hash": "3Mjm17wCIaZ", "uri": "/contracts/3Mjm17wCIaZ#new-commitments", "label": "Research Agreement", "score": 28.6967716217, "published": true}, {"hash": "gcaJOlBYAxA", "uri": "/contracts/gcaJOlBYAxA#new-commitments", "label": "Research Agreement", "score": 28.439458847, "published": true}], "size": 5, "snippet": "The Research Organization shall make no new commitments funded under this Agreement, after receipt of a written termination notice from AISC and shall, to the extent feasible, cancel all outstanding commitments and contracts by the termination date.", "hash": "97931b2b52b9529efb4491b328330da0", "id": 5}, {"snippet_links": [{"key": "of-the-buyer", "type": "clause", "offset": [34, 46]}, {"key": "seller-shall", "type": "clause", "offset": [99, 111]}, {"key": "prior-to-the-closing", "type": "clause", "offset": [112, 132]}, {"key": "in-accordance-with", "type": "definition", "offset": [148, 166]}, {"key": "bid-procedures-order", "type": "clause", "offset": [171, 191]}, {"key": "agreement-or", "type": "definition", "offset": [212, 224]}, {"key": "with-respect-to", "type": "clause", "offset": [236, 251]}, {"key": "the-assets", "type": "clause", "offset": [252, 262]}, {"key": "operation-of-the-business", "type": "clause", "offset": [313, 338]}, {"key": "existing-agreements", "type": "clause", "offset": [368, 387]}, {"key": "relating-to", "type": "definition", "offset": [388, 399]}, {"key": "otherwise-dispose-of", "type": "definition", "offset": [497, 517]}, {"key": "personal-property", "type": "definition", "offset": [547, 564]}, {"key": "on-schedule", "type": "definition", "offset": [714, 725]}, {"key": "pursuant-to", "type": "clause", "offset": [737, 748]}, {"key": "approved-by", "type": "definition", "offset": [773, 784]}, {"key": "bankruptcy-court", "type": "definition", "offset": [789, 805]}, {"key": "date-hereof", "type": "clause", "offset": [816, 827]}], "samples": [{"hash": "dNHwhK0x0g6", "uri": "/contracts/dNHwhK0x0g6#new-commitments", "label": "Asset Purchase Agreement (Borders Group Inc)", "score": 22.5058174133, "published": true}, {"hash": "eQyWZovJULB", "uri": "/contracts/eQyWZovJULB#new-commitments", "label": "Asset Purchase Agreement", "score": 22.5028152466, "published": true}, {"hash": "6o5dCWKH7ux", "uri": "/contracts/6o5dCWKH7ux#new-commitments", "label": "Asset Purchase Agreement", "score": 21.9924716949, "published": true}], "size": 3, "snippet": "Without the prior written consent of the Buyer (which shall not be unreasonably withheld), neither Seller shall prior to the Closing (a) other than in accordance with the Bid Procedures Order, enter into any new agreement or commitment with respect to the Assets or the Business other than in the ordinary course operation of the Business, (b) modify or terminate any existing agreements relating to the Assets other than in the ordinary course operation of the Business, or (c) encumber, sell or otherwise dispose of any of the Assets other than personal property that is replaced by equivalent property or consumed in the normal, ordinary course operation of the Business, except for any commitment as set forth on Schedule 6.4 sought pursuant to motions pending with or approved by the Bankruptcy Court as of the date hereof.", "hash": "16f4c1b563d9133a2872047761899977", "id": 6}, {"snippet_links": [{"key": "neither-party", "type": "definition", "offset": [0, 13]}, {"key": "expenses-related-to-this-agreement", "type": "clause", "offset": [29, 63]}, {"key": "after-expiration", "type": "clause", "offset": [64, 80]}, {"key": "mutual-termination", "type": "clause", "offset": [82, 100]}, {"key": "notice-of-a", "type": "clause", "offset": [107, 118]}, {"key": "unilateral-termination", "type": "clause", "offset": [119, 141]}, {"key": "to-the-extent", "type": "clause", "offset": [152, 165]}, {"key": "commitments-and-contracts", "type": "clause", "offset": [199, 224]}, {"key": "termination-date", "type": "definition", "offset": [232, 248]}, {"key": "authority-to", "type": "definition", "offset": [313, 325]}, {"key": "subsequent-to-the", "type": "clause", "offset": [370, 387]}, {"key": "during-the-term-of-the-agreement", "type": "clause", "offset": [441, 473]}, {"key": "research-and-development-activities", "type": "clause", "offset": [493, 528]}, {"key": "joint-work-statement", "type": "definition", "offset": [546, 566]}], "samples": [{"hash": "kKaeRpRv60A", "uri": "/contracts/kKaeRpRv60A#new-commitments", "label": "Cooperative Research and Development Agreement (BridgeBio Oncology Therapeutics, Inc.)", "score": 37.3586584531, "published": true}, {"hash": "6IorhYCwDu7", "uri": "/contracts/6IorhYCwDu7#new-commitments", "label": "Cooperative Research and Development Agreement (TheRas, Inc.)", "score": 36.4661178589, "published": true}], "size": 3, "snippet": "Neither Party will incur new expenses related to this Agreement after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that Leidos Biomedical will have the authority to retain and expend any funds for up to [***] subsequent to the termination date to cover any unpaid costs obligated during the term of the Agreement in undertaking the research and development activities set forth in the Joint Work Statement.", "hash": "3b748d529bbac6ac9aa82b275130dbde", "id": 7}, {"snippet_links": [{"key": "no-party", "type": "clause", "offset": [0, 8]}, {"key": "to-this-agreement", "type": "clause", "offset": [44, 61]}, {"key": "mutual-termination", "type": "clause", "offset": [70, 88]}, {"key": "notice-of-a", "type": "clause", "offset": [92, 103]}, {"key": "unilateral-termination", "type": "clause", "offset": [104, 126]}, {"key": "to-the-extent", "type": "clause", "offset": [138, 151]}, {"key": "commitments-and-contracts", "type": "clause", "offset": [185, 210]}, {"key": "termination-date", "type": "definition", "offset": [218, 234]}], "samples": [{"hash": "kZYbZBeetQ", "uri": "/contracts/kZYbZBeetQ#new-commitments", "label": "Collaborative Research and Development Agreement", "score": 21.0, "published": true}, {"hash": "iejffE9yLP5", "uri": "/contracts/iejffE9yLP5#new-commitments", "label": "Co Development Agreement", "score": 21.0, "published": true}], "size": 2, "snippet": "No Party shall make new commitments related to this Agreement after a mutual termination or notice of a unilateral termination and shall, to the extent feasible, cancel all outstanding commitments and contracts by the termination date.", "hash": "9f8855ead75fb52e5a8d5943b2d21b81", "id": 8}, {"snippet_links": [{"key": "neither-party", "type": "definition", "offset": [0, 13]}, {"key": "related-to", "type": "clause", "offset": [38, 48]}, {"key": "after-expiration", "type": "clause", "offset": [60, 76]}, {"key": "mutual-termination", "type": "clause", "offset": [78, 96]}, {"key": "notice-of-a", "type": "clause", "offset": [103, 114]}, {"key": "unilateral-termination", "type": "clause", "offset": [115, 137]}, {"key": "to-the-extent", "type": "clause", "offset": [148, 161]}, {"key": "commitments-and-contracts", "type": "clause", "offset": [195, 220]}, {"key": "termination-date", "type": "definition", "offset": [228, 244]}, {"key": "authority-to", "type": "definition", "offset": [295, 307]}, {"key": "received-by", "type": "definition", "offset": [344, 355]}, {"key": "subsequent-to-the", "type": "clause", "offset": [378, 395]}, {"key": "expiration-or-termination", "type": "clause", "offset": [396, 421]}, {"key": "term-of-the", "type": "clause", "offset": [474, 485]}, {"key": "research-and-development-activities", "type": "clause", "offset": [511, 546]}, {"key": "research-plan", "type": "definition", "offset": [564, 577]}, {"key": "public-health-service", "type": "definition", "offset": [662, 683]}, {"key": "agreement-for", "type": "clause", "offset": [721, 734]}, {"key": "clinical-research", "type": "clause", "offset": [750, 767]}], "samples": [{"hash": "do93g6OpnFK", "uri": "/contracts/do93g6OpnFK#new-commitments", "label": "Cooperative Research and Development Agreement (Kite Pharma, Inc.)", "score": 25.377822876, "published": true}, {"hash": "doHeAdFfhfn", "uri": "/contracts/doHeAdFfhfn#new-commitments", "label": "Cooperative Research and Development Agreement (Kite Pharma, Inc.)", "score": 25.2546195984, "published": true}], "size": 2, "snippet": "Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that ICD will have the authority to retain and expend any funds already received by ICD for up to [\u2026***\u2026] subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 51 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH", "hash": "5fa6d2109f808dd85f91692a301b87ac", "id": 9}, {"snippet_links": [{"key": "neither-party", "type": "definition", "offset": [0, 13]}, {"key": "related-to", "type": "clause", "offset": [38, 48]}, {"key": "after-expiration", "type": "clause", "offset": [60, 76]}, {"key": "mutual-termination", "type": "clause", "offset": [78, 96]}, {"key": "notice-of-a", "type": "clause", "offset": [103, 114]}, {"key": "unilateral-termination", "type": "clause", "offset": [115, 137]}, {"key": "to-the-extent", "type": "clause", "offset": [148, 161]}, {"key": "commitments-and-contracts", "type": "clause", "offset": [195, 220]}, {"key": "termination-date", "type": "definition", "offset": [228, 244]}, {"key": "authority-to", "type": "definition", "offset": [294, 306]}, {"key": "subsequent-to-the", "type": "clause", "offset": [351, 368]}, {"key": "expiration-or-termination", "type": "clause", "offset": [369, 394]}, {"key": "term-of-the", "type": "clause", "offset": [447, 458]}, {"key": "research-and-development-activities", "type": "clause", "offset": [484, 519]}, {"key": "research-plan", "type": "definition", "offset": [537, 550]}, {"key": "related-expenses", "type": "definition", "offset": [573, 589]}, {"key": "stability-testing", "type": "definition", "offset": [659, 676]}, {"key": "crada-data", "type": "definition", "offset": [700, 710]}, {"key": "crada-materials", "type": "definition", "offset": [715, 730]}, {"key": "ongoing-clinical-trials", "type": "clause", "offset": [743, 766]}, {"key": "human-subjects", "type": "definition", "offset": [809, 823]}, {"key": "deputy-director", "type": "clause", "offset": [949, 964]}, {"key": "date-title", "type": "clause", "offset": [1040, 1050]}, {"key": "purpose-of-this-amendment", "type": "clause", "offset": [1095, 1120]}, {"key": "terms-of-the", "type": "clause", "offset": [1142, 1154]}, {"key": "cooperative-research-and-development-agreement", "type": "definition", "offset": [1172, 1218]}, {"key": "the-original", "type": "clause", "offset": [1317, 1329]}, {"key": "as-amended", "type": "definition", "offset": [1337, 1347]}, {"key": "full-force-and-effect", "type": "clause", "offset": [1392, 1413]}, {"key": "the-parties-agree-as-follows", "type": "clause", "offset": [1415, 1443]}], "samples": [{"hash": "8YP4jSO9hYH", "uri": "/contracts/8YP4jSO9hYH#new-commitments", "label": "Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)", "score": 27.0068454742, "published": true}, {"hash": "5HWrGj1sQ5H", "uri": "/contracts/5HWrGj1sQ5H#new-commitments", "label": "Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)", "score": 26.856262207, "published": true}], "size": 2, "snippet": "Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that IC will have the authority to retain and expend any funds for up to [***] subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan and for ongoing CRADA-related expenses that arise after the expiration or termination date, such as vaccine stability testing, managing or analyzing CRADA Data and CRADA Materials, continuing ongoing clinical trials, and conducting follow-up observations of Human Subjects treated under the CRADA, such that the authority to make these expenditures will survive the CRADA. [***] 6/25/13 [***] Date Deputy Director for Clinical and Translational Research, NCI [***] 28 May 2013 Name: [***] Date Title: President, BN Immunotherapeutics, Inc. The purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for these changes, all other provisions of the original CRADA, as amended by Amendment #1 on June 21, 2013, remain in full force and effect. The Parties agree as follows:", "hash": "eafd3470d2de54ef8b8c627814cc1a77", "id": 10}], "next_curs": "ClgSUmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjQLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhhuZXctY29tbWl0bWVudHMjMDAwMDAwMGEMogECZW4YACAA", "clause": {"parents": [["expiration-and-termination", "Expiration and Termination"], ["termination", "Termination"], ["the-credits", "The Credits"], ["miscellaneous", "Miscellaneous"], ["new-commitments", "New Commitments"]], "title": "New Commitments", "size": 155, "children": [["new-commitments", "New Commitments"], ["governing-law", "Governing Law"], ["headings", "Headings"], ["tolling-remedy", "Tolling Remedy"], ["additional-remedies", "Additional Remedies"]], "id": "new-commitments", "related": [["incremental-commitments", "Incremental Commitments", "Incremental Commitments"], ["additional-commitments", "Additional Commitments", "Additional Commitments"], ["term-commitments", "Term Commitments", "Term Commitments"], ["loan-commitments", "Loan Commitments", "Loan Commitments"], ["revolving-commitments", "Revolving Commitments", "Revolving Commitments"]], "related_snippets": [], "updated": "2026-05-15T04:24:17+00:00", "also_ask": ["What are the essential elements that must be included in a 'New Commitments' clause to ensure clarity and enforceability?", "How can parties strategically limit or expand the scope of new commitments during negotiations?", "What are the most common risks or pitfalls associated with poorly drafted 'New Commitments' clauses?", "How do courts typically interpret and enforce 'New Commitments' provisions in contract disputes?", "How does the treatment of 'New Commitments' differ across key jurisdictions or under different governing laws?"], "drafting_tip": "Specify the process for creating new commitments to ensure clarity; require written consent from all parties to prevent unauthorized obligations; define the scope and limits of new commitments to avoid disputes.", "explanation": "The \"New Commitments\" clause defines the process and conditions under which additional obligations or responsibilities may be introduced into an existing agreement. Typically, this clause outlines how parties can propose, negotiate, and formalize new commitments, often requiring mutual consent and written documentation. For example, it may specify that any new service requirements or deliverables must be agreed upon in writing before becoming binding. The core function of this clause is to provide a clear and structured mechanism for expanding the scope of the agreement while ensuring that all parties are aware of and agree to any new obligations, thereby preventing misunderstandings or disputes."}, "json": true, "cursor": ""}}